CN1223376C - 丙型肝炎多表位抗原复合体多肽疫苗及其制备方法和应用 - Google Patents
丙型肝炎多表位抗原复合体多肽疫苗及其制备方法和应用 Download PDFInfo
- Publication number
- CN1223376C CN1223376C CN 01108683 CN01108683A CN1223376C CN 1223376 C CN1223376 C CN 1223376C CN 01108683 CN01108683 CN 01108683 CN 01108683 A CN01108683 A CN 01108683A CN 1223376 C CN1223376 C CN 1223376C
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- antigen complex
- complex polypeptide
- polyepitope
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 71
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 70
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 70
- 239000000427 antigen Substances 0.000 title claims abstract description 65
- 102000036639 antigens Human genes 0.000 title claims abstract description 65
- 108091007433 antigens Proteins 0.000 title claims abstract description 65
- 208000005176 Hepatitis C Diseases 0.000 title claims abstract description 46
- 229960005486 vaccine Drugs 0.000 title claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 36
- 238000000746 purification Methods 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 238000013461 design Methods 0.000 claims abstract description 6
- 238000000926 separation method Methods 0.000 claims abstract description 6
- 150000001413 amino acids Chemical class 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims abstract description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 27
- 239000000047 product Substances 0.000 claims description 22
- 239000002953 phosphate buffered saline Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 9
- 235000018102 proteins Nutrition 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 230000006698 induction Effects 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 208000006454 hepatitis Diseases 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 4
- 238000002270 exclusion chromatography Methods 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 238000010612 desalination reaction Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000002474 experimental method Methods 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 238000002525 ultrasonication Methods 0.000 claims description 3
- 108091081024 Start codon Proteins 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 210000003000 inclusion body Anatomy 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 238000004255 ion exchange chromatography Methods 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 abstract description 4
- 230000002163 immunogen Effects 0.000 abstract description 4
- 238000001514 detection method Methods 0.000 abstract description 3
- 241000700605 Viruses Species 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- 229940124737 hepatitis-C vaccine Drugs 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229910018626 Al(OH) Inorganic materials 0.000 description 3
- 206010019799 Hepatitis viral Diseases 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 201000001862 viral hepatitis Diseases 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102400000827 Saposin-D Human genes 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 241001536481 Banzi virus Species 0.000 description 1
- 101100493713 Caenorhabditis elegans bath-45 gene Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101800001632 Envelope protein E Proteins 0.000 description 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000034175 Portosinusoidal vascular disease Diseases 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002324 hematogenic effect Effects 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
组别 | n | 抗体滴度 |
实验组对照组 | 1010 | 1∶40- |
组别 | Al(OH)3+甲醛(μg) | Al(OH)3(μg) | 完全福氏佐剂(μg) | 对照 | |||||||||
5 | 10 | 20 | 30 | 5 | 10 | 20 | 30 | 5 | 10 | 20 | 30 | ||
1∶30 | 1∶60 | 1∶30 | 1∶30 | 1∶30 | 1∶30 | 1∶30 | 1∶30 | 1∶30 | 1∶60 | 1∶30 | 1∶30 | - |
组别 | 对照组 | Al(OH)3+甲醛佐剂组 |
谷丙转氨酶水平(U/L) | 21 | 19 |
AL(OH)3佐剂组 | 福氏佐剂组 | 无佐剂组 | |
抗体滴度 | 1∶40 | 1∶40 | 1∶2 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 01108683 CN1223376C (zh) | 2001-07-24 | 2001-07-24 | 丙型肝炎多表位抗原复合体多肽疫苗及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 01108683 CN1223376C (zh) | 2001-07-24 | 2001-07-24 | 丙型肝炎多表位抗原复合体多肽疫苗及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1347735A CN1347735A (zh) | 2002-05-08 |
CN1223376C true CN1223376C (zh) | 2005-10-19 |
Family
ID=4657479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 01108683 Expired - Fee Related CN1223376C (zh) | 2001-07-24 | 2001-07-24 | 丙型肝炎多表位抗原复合体多肽疫苗及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1223376C (zh) |
-
2001
- 2001-07-24 CN CN 01108683 patent/CN1223376C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1347735A (zh) | 2002-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1211488C (zh) | 改构的植物病毒作为异源肽的载体 | |
CN1091978A (zh) | 粒细胞-巨噬细胞-集落刺激因子作为疫苗佐剂的用途 | |
WO2010086743A2 (en) | Compositions and methods that enhance an immune response | |
CN1665528A (zh) | 佐剂病毒颗粒 | |
CN102449172A (zh) | 施用针对登革病毒的疫苗的组合物和方法 | |
نصرتی et al. | A novel multi-epitope vaccine for cross protection against hepatitis C virus (HCV): An immunoinformatics approach | |
CN101062941A (zh) | 一种重组戊型肝炎病毒蛋白、其制备方法及用途 | |
CN1800854A (zh) | 肾综合征出血热快速金标诊断试纸条 | |
CN102058881B (zh) | 预防肠道病毒71型感染的基因重组疫苗及其制备方法 | |
CN103539839A (zh) | 肠道病毒71型的vp2抗原的中和表位多肽及其用途 | |
Wang et al. | Expression of codon-optimized PDCoV-RBD protein in baculovirus expression system and immunogenicity evaluation in mice | |
CN102406929B (zh) | 一种共表达分子佐剂加强型二价口蹄疫蛋白工程疫苗 | |
CN106480070A (zh) | 一种用于展示目的多肽的多肽载体及其用途 | |
CN1223376C (zh) | 丙型肝炎多表位抗原复合体多肽疫苗及其制备方法和应用 | |
CN1164331C (zh) | 一种人乙型肝炎核酸疫苗 | |
WO2014186409A1 (en) | Immunogenic compositions for inhibiting hepatitis d virus | |
CN1185254C (zh) | 丙型肝炎病毒第一高变区抗原及其融合抗原 | |
CN1438238A (zh) | 丙型肝炎病毒高变区1合成肽及其应用 | |
CN103566369B (zh) | 一种在慢性乙肝病毒感染状态下诱导机体产生特异性免疫的乙肝疫苗 | |
CN101961487A (zh) | 细粒棘球蚴基因工程疫苗候选分子p-29 | |
CN1063756C (zh) | 同时含有乙肝病毒和丙肝病毒核心抗原的双重抗原 | |
CN1645148A (zh) | 检测猪胸膜肺炎放线杆菌野毒感染的试剂盒 | |
CN1086421C (zh) | 丙型肝炎病毒复合多价疫苗基因的合成与克隆 | |
CN1258538C (zh) | 一种重组蛋白 | |
CN1305527C (zh) | 乙型肝炎治疗疫苗及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHUXIONG LAOBO YUNTANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHUXIONG BOYUN BIOLOGICAL DEVELOPMENT CO., LTD. Effective date: 20070928 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070928 Address after: 650000 pharmaceutical industry park, Chuxiong economic and Technological Development Zone, Chuxiong, Yunnan Patentee after: Chuxiong Laobayuntang Pharmaceutical Co., Ltd. Address before: High tech Development Zone, Yunnan province Kunming Kanghong District 650118 city 26-3-101 Boyun biological company Kunming Representative Office Patentee before: Chuxiong Boyun Biological Development Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051019 Termination date: 20180724 |
|
CF01 | Termination of patent right due to non-payment of annual fee |